Form 4: Alnylam Director Arbuckle Granted Stock Options

Alnylam Pharmaceuticals director Stuart A. Arbuckle was granted 3,279 stock options with a vesting schedule over three years.

Summary

• Stuart A. Arbuckle, a Director of Alnylam Pharmaceuticals, Inc. (ALNY), was granted stock options.
• The grant occurred on January 5, 2026.
• He received 3,279 stock options, each with an exercise price of $397.83.
• These options will vest in three equal annual installments, with one-third vesting on the first, second, and third anniversaries of the grant date.
• The options have an expiration date of January 5, 2036.
• Following this transaction, Arbuckle beneficially owns 3,279 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event for the individual, aligning their interests with the company's long-term performance. It's a standard compensation practice, indicating stability rather than a significant shift in company outlook.

Positives

• Grant of 3,279 stock options to Director Stuart A. Arbuckle aligns his interests with long-term shareholder value.
• The options have a 10-year expiration date (January 5, 2036), providing a long window for potential value realization.

Negatives

• No specific negatives are identified in this filing, which reports a standard equity grant.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The stock options granted to Director Stuart A. Arbuckle are structured to vest over a three-year period, with one-third of the shares vesting on each of the first, second, and third anniversaries of the January 5, 2026 grant date, aligning future compensation with company performance.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a standard component of executive and director compensation packages designed to incentivize long-term commitment and align interests with shareholder value.

Comparison to Industry Standards

• The grant of stock options with a multi-year vesting schedule is a standard compensation practice for directors in publicly traded biotechnology companies, comparable to practices at peers like Moderna or BioNTech, aiming to retain talent and align long-term incentives.
• The exercise price of $397.83 per option is set at the market price on the grant date, which is typical for incentive stock options across the industry.

Related Party Transactions

• The grant of stock options to Stuart A. Arbuckle, a Director of Alnylam Pharmaceuticals, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with long-term shareholder value, potentially encouraging decisions that benefit the stock price over time.
• Employees: This filing specifically relates to director compensation and does not directly impact the broader employee base, though it reflects standard corporate compensation practices.

Next Steps

• One-third of the granted stock options will vest on January 5, 2027.
• Another one-third of the granted stock options will vest on January 5, 2028.
• The final one-third of the granted stock options will vest on January 5, 2029.
• The options can be exercised at any time after vesting until their expiration on January 5, 2036.

Key Dates

Keywords

Alnylam Pharmaceuticals, ALNY, Stuart A. Arbuckle, Stock Options, Director Compensation, SEC Form 4, Equity Grant, Beneficial Ownership